psoriasis vulgaris
Conditions
Interventions
investigational material(s)
Generic name etc : Secukinumab(Genetical Recombination)
INN of investigational material : -
Therapeutic category code : 399 Agents affecting metabolism, n.e.c.
Dosage and A
Sponsors
Novartis Pharma K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who provide informed consent (written or oral) for study participation 2.Age >=20 at study participation 3.Patients with a documented diagnosis of psoriasis vulgaris with or without PsA and were/are treated with secukinumab according to the Japanese package insert of secukinumab 4.Psoriasis with or without PsA patients who started secukinumab at the participating dermatology institutions after 26-Dec-2014 and whose first day of secukinumab treatment is >52 weeks before the IC collection date
Exclusion criteria
Exclusion criteria: 1.Patients whose follow-up visit to the participating institution is <2 after secukinumab initiation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| other The primary endpoint is the time to discontinuation of secukinumab in psoriasis with or without PsA patients followed at medical institutions participating in this study. The estimate of retention rate (the proportion of patients who do not discontinue secukinumab) at Week 52 will be derived. | — |
Secondary
| Measure | Time frame |
|---|---|
| other Secukinumab retention rate at other time points other Factors associated with secukinumab retention rate efficacy Secukinumab effectiveness other factors associated with secukinumab effectiveness | — |
Countries
Japan
Outcome results
None listed